Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
A comparative study into the mechanisms of action of anti-tumor necrosis factor α, anti-CD4, and combined anti-tumor necrosis factor α/anti-CD4 treatment in early collagen-induced arthritis
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Journal Article
  • Authors:
    Marinova-Mutafchieva L, Williams RO, Mauri C, Mason LJ, Walmsley MJ, Taylor PC, Feldmann M, Maini RN
  • Publication date:
  • Pagination:
    638, 644
  • Journal:
    Arthritis and Rheumatism
  • Volume:
  • Issue:
  • Status:
  • Print ISSN:
Objective. Anti-tumor necrosis factor α (anti-TNFα) therapy is very effective in rheumatoid arthritis (RA), whereas depleting anti-CD4 therapy is relatively ineffective. To explain the differences in efficacy between these 2 therapies, we used an animal model of RA to compare their effects on different aspects of the disease process. Methods. Mice with collagen-induced arthritis were treated with depleting anti-CD4 monoclonal antibodies (mAb), anti-TNFα mAb, or phosphate buffered saline. Another group was given a combination of anti-TNFα plus anti-CD4. The treatments were compared for their ability to down-regulate the expression of inflammatory cytokines and adhesion molecules, reduce the cellularity of the joint, and inhibit Th1 activity. Results. Anti-TNFα significantly reduced the numbers of cells expressing TNFα, interleukin-1β (IL-1β), very late activation antigen 4 (VLA-4), vascular cell adhesion molecule 1 (VCAM-1), and numbers of CD4+ T cells and macrophages in the joint. Anti-CD4 treatment led to a small reduction in the expression of TNFα, IL-1β, VLA-4, and VCAM-1, but this did not reach statistical significance. Depleting anti-CD4 was also surprisingly ineffective in eliminating CD4+ T cells from the joint. Anti-TNFα therapy was also more effective than anti-CD4 in reducing Th1 activity, as assessed by the production of interferon-γ in lymph node cell cultures. There was a synergistic relationship between anti-TNFα and anti-CD4 in the reduction of histologic score and inhibition of TNFα/IL-1β expression in the joints. Conclusion. The efficacy of the 3 treatments correlated with their ability to modulate the expression of inflammatory cytokines and adhesion molecules in the joint, reduce the cellularity of the joint, and inhibit Th1 activity. This kind of analysis may prove useful in the testing of novel therapies for RA.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Div of Infection & Immunity
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by